Portal de Periódicos da CAPES

The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease

2015; Oxford University Press; Volume: 10; Issue: 3 Linguagem: Inglês

10.1093/ecco-jcc/jjv213

1876-4479

Marcus Harbord, Vito Annese, Stephan R. Vavricka, Matthieu Allez, Manuel Barreiro‐de Acosta, Kirsten Muri Boberg, Johan Burisch, Martine De Vos, Annemarie de Vries, Andrew D. Dick, Pascal Juillerat, Tom H. Karlsen, Ioannis E. Κoutroubakis, Péter L. Lakatos, Tim Orchard, Pavol Papay, Tim Raine, Max Reinshagen, Diamant Thaçi, Herbert Tilg, Franck Carbonnel,

Liver Diseases and Immunity

This is the first European Crohn’s and Colitis Organisation [ECCO] consensus guideline that addresses extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. It has been drafted by 21 ECCO members from 13 European countries. Although this is the first ECCO consensus guideline that primarily addresses EIMs, it is partly derived from, updates, and replaces previous ECCO consensus advice on EIMs, contained within the consensus guidelines for Crohn’s disease1 [CD] and ulcerative colitis2 [UC]. The strategy to define consensus was similar to that previously described in other ECCO consensus guidelines [available at www.ecco-ibd.eu]. Briefly, topics were selected by the ECCO guidelines committee [GuiCom]. ECCO members were selected to form working groups. Provisional ECCO Statements and supporting text were written following a comprehensive literature review, then refined following two voting rounds which included national representative participation by ECCO’s 35 member countries. The level of evidence was graded according to the Oxford Centre for Evidence-based Medicine [www.cebm.net]. The ECCO Statements were finalised by the authors at a meeting in Vienna in October 2014 and represent consensus with agreement of at least 80% of participants. Complete consensus [100% agreement] was reached for most statements. The supporting text was then finalised under the direction of each working group leader [VA, SV, FC, MH] before being integrated by the two consensus leaders [MH, FC]. This consensus guideline is pictorially represented within the freely available ECCO e-Guide [http://www.e-guide.ecco-ibd.eu/]. Up to 50% of patients with inflammatory bowel disease [IBD] experience at least one extra-intestinal manifestation [EIM], which can present before IBD is diagnosed.34,5,6 EIMs adversely impact upon patients’ quality of life and some, such as primary sclerosing cholangitis [PSC] or venous thromboembolism [VTE], can be life-threatening. The probability of developing EIMs increases with disease duration and in patients who already have one EIM.7 …